复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 11-14 16:08:11

67.100

+2.350

+3.63%

最高69.600	最低63.350	成交量164.99万
今开64.500	昨收64.750	日振幅9.65%
总市值364.69亿	流通市值109.66亿	总股本5.43亿
成交额1.11亿	换手率1.01%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":67.1,"timestamp":1763107691009,"preClose":64.75,"halted":0,"volume":1649900,"delay":0,"floatShares":163428541,"shares":543494853,"eps":1.6518642811562205,"marketStatus":"休市中","change":2.35,"latestTime":"11-14 16:08:11","open":64.5,"high":69.6,"low":63.35,"amount":111145991,"amplitude":0.096525,"askPrice":67.1,"askSize":3900,"bidPrice":66.75,"bidSize":11600,"shortable":3,"etf":0,"ttmEps":1.6595676369318804,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763343000000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":64.75,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":1.1820298788058476,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2583685745","title":"复宏汉霖HLX43启动II期临床 适应症为胰腺导管腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2583685745","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583685745?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:03","pubTimestamp":1763114580,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，上海复宏汉霖生物技术股份有限公司/上海复宏汉霖生物医药有限公司的一项评估HLX43 在晚期胰腺癌受试者中有效性和安全性的II期临床研究已启动。本次试验主要目的是评估HLX43在晚期胰腺癌中的临床疗效。HLX43为生物制品，适应症为胰腺导管腺癌。胰腺导管腺癌是常见的胰腺恶性肿瘤，早期症状不明显，后期可出现腹痛、黄疸、消瘦等。目前，该实验状态为进行中，目标入组人数100人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114190543a6f961c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114190543a6f961c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2583575864","title":"复宏汉霖(02696)：FDA批准HLX11(帕妥珠单抗，美国商品名：POHERDY®)用于HER2阳性早期乳腺癌的新辅助/辅助和转移性乳腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2583575864","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583575864?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:35","pubTimestamp":1763109305,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，集团收到美国食品药品管理局的批准函，POHERDY 420mg/14mL注射液的生物制品许可申请获FDA批准，该商品名由N.V.Organon于美国注册商标。此次FDA的批准主要是基于对HLX11与其参照药一系列比对研究数据的全面审查，包括分析相似性研究及临床比对研究。HLX11获准用于参照药Perjeta在美国已获批的所有适应症。HLX11是公司自主研发的帕妥珠单抗生物类似药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：FDA批准HLX11(帕妥珠单抗，美国商品名：POHERDY®)用于HER2阳性早期乳腺癌的新辅助/辅助和转移性乳腺癌治疗","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2583857266","title":"每日卖空追踪 | 复宏汉霖 11月14日卖空量成交2.35万股，卖空比例为1.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583857266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583857266?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:30","pubTimestamp":1763109033,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间11月14日，涨3.63%，卖空量成交2.35万股，较上一交易日减少62.52%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141641169768ff2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141641169768ff2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2583408445","title":"复宏汉霖(02696.HK)再涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583408445","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583408445?lang=zh_cn&edition=full","pubTime":"2025-11-14 10:49","pubTimestamp":1763088550,"startTime":"0","endTime":"0","summary":"每经AI快讯，复宏汉霖(02696.HK)再涨超5%，截至发稿，涨6.02%，报68.7港元，成交额3425.31万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511143564624667.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511143564624667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2583857026","title":"复宏汉霖盘中异动 大幅拉升5.02%报68.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583857026","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583857026?lang=zh_cn&edition=full","pubTime":"2025-11-14 10:24","pubTimestamp":1763087054,"startTime":"0","endTime":"0","summary":"2025年11月14日早盘10时24分，复宏汉霖股票出现异动，股价急速上涨5.02%。截至发稿，该股报68.000港元/股，成交量36.79万股，换手率0.23%，振幅7.18%。资金方面，该股资金流入1132.41万港元，流出1218.32万港元。复宏汉霖股票所在的生物技术行业中，整体跌幅为1.29%。这并非博裕资本首次青睐复宏汉霖，早在今年6月18日，该机构就已斥资2126.73万港元增持，将好仓比例从4.89%提升至5.15%，跨越5%的“举牌线”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111410241495037e8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111410241495037e8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2583531435","title":"港股异动 | 复宏汉霖(02696)现涨超4% 地舒单抗BILDYOS和BILPREVDA获英国批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583531435","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583531435?lang=zh_cn&edition=full","pubTime":"2025-11-13 14:41","pubTimestamp":1763016099,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖现涨超4%，截至发稿，涨4.53%，报64.6港元，成交额7948.42万港元。消息面上，复宏汉霖宣布，英国药品和健康产品管理局已批准地舒单抗BILDYOS和BILPREVDA的上市许可，两款产品覆盖原研药在英国已获批的所有适应症。据悉，2022年，复宏汉霖授予Organon对包括BILDYOS和BILPREVDA在内的多个生物类似药在除中国以外的全球区域的独家商业化权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"港股异动 | 复宏汉霖(02696)现涨超4% 地舒单抗BILDYOS和BILPREVDA获英国批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2583566580","title":"博裕资本再出手！增持复宏汉霖(02696.HK)背后的价值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2583566580","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583566580?lang=zh_cn&edition=full","pubTime":"2025-11-13 08:58","pubTimestamp":1762995536,"startTime":"0","endTime":"0","summary":"博裕资本（Boyu Capital Investment Management Limited）接连出手，分别买入复宏汉霖262,500股及80,000股H股，两次增持后其H股好仓比例由5.84%跃升至7%。","market":"us","thumbnail":"https://img7.gelonghui.com/column/5.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/5.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3184605","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02696","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2582034364","title":"药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2582034364","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582034364?lang=zh_cn&edition=full","pubTime":"2025-11-12 11:29","pubTimestamp":1762918190,"startTime":"0","endTime":"0","summary":"【药企豪赌 肺癌下一代免疫“新药王”争夺赛已打响】凭借在肺癌领域的突出表现，默沙东的PD-1单抗K药连续在2023年、2024年成为全球药王，年销售额均突破200亿美元。谁能成为肺癌领域下一代免疫“新王”，一场争夺赛在药企中已打响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511123562061651.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511123562061651.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BPRC5H50.USD","LU2097828631.EUR","BK1574","LU0348767384.USD","LU2097828714.EUR","IE00B5MMRT66.SGD","LU0502904849.HKD","LU0053666078.USD","LU0455707207.USD","LU2328871848.SGD","LU0540923850.HKD","LU2476274308.USD","HK0000165453.HKD","LU2476274720.SGD","LU2488822045.USD","LU0417516738.SGD","LU1969619763.USD","LU2487616109.SGD","LU0417516571.SGD","LU0348735423.USD","LU1961090484.USD","LU0348827113.USD","LU0634319403.HKD","LU1720050803.USD","LU2097828805.USD","IE00B543WZ88.USD","LU0348766576.USD","02696","LU0348783233.USD","BK1161","LU2097828557.USD","LU2399975544.HKD","LU1794554557.SGD","LU2778985437.USD","BK4588","LU0348784397.USD","LU0561508036.HKD","LU0348825331.USD","BK1583","L","LU0210528500.USD","LU0417516902.SGD","01801","BK1589","09926","LU2242644610.SGD","BK4107","BK4585","ORR","LU2097828474.EUR"],"gpt_icon":0},{"id":"2582638603","title":"Boyu Capital Opportunities Master Fund增持复宏汉霖(02696)26.25万股 每股均价61.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582638603","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582638603?lang=zh_cn&edition=full","pubTime":"2025-11-11 18:54","pubTimestamp":1762858460,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月6日，Boyu Capital Opportunities Master Fund增持复宏汉霖(02696)26.25万股，每股均价61.28港元，总金额为1608.6万港元。增持后最新持股数目约为980.57万股，最新持股比例6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Boyu Capital Opportunities Master Fund增持复宏汉霖(02696)26.25万股 每股均价61.28港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2582165399","title":"每日卖空追踪 | 复宏汉霖 11月11日卖空量成交1.69万股，卖空比例为1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582165399","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582165399?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:30","pubTimestamp":1762849832,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间11月11日，跌0.73%，卖空量成交1.69万股，较上一交易日减少37.41%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111163437a6f184c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111163437a6f184c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2582025818","title":"影响重大！中国又一领域创新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2582025818","media":"投资家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582025818?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:15","pubTimestamp":1762776936,"startTime":"0","endTime":"0","summary":"值得一提的是，正是国产创新药企的推陈出新，才有了今日中国在创新药领域的不断突破。要知道，肺癌始终高居全球及中国恶性肿瘤发病率榜首，而复宏汉霖作为深耕该领域的先行者，已成功推出9款上市产品，惠及全球超90万名患者。因为彼时，中国创新药研发尚处萌芽，进口原研生物药的高昂价格令众多患者望而却步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110211412a6ef9a7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110211412a6ef9a7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696","HK0000165453.HKD","BK1574","06978"],"gpt_icon":0},{"id":"2582967820","title":"Boyu Capital Group Holdings Ltd.增持复宏汉霖(02696)8万股 每股均价61.78港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582967820","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582967820?lang=zh_cn&edition=full","pubTime":"2025-11-10 18:51","pubTimestamp":1762771868,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，11月10日，Boyu Capital Group Holdings Ltd.增持复宏汉霖(02696)8万股，每股均价61.78港元，总金额为494.24万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20251110/20251110185147_93975.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251110/20251110185147_93975.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Boyu Capital Group Holdings Ltd.增持复宏汉霖(02696)8万股 每股均价61.78港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2582223458","title":"每日卖空追踪 | 复宏汉霖 11月10日卖空量成交1.58万股，卖空比例为0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582223458","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582223458?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:30","pubTimestamp":1762763429,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间11月10日，涨1.39%，卖空量成交1.58万股，较上一交易日减少68.65%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111016345294fafa84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111016345294fafa84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2582822820","title":"复宏汉霖11月10日主力净流入493.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2582822820","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582822820?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:15","pubTimestamp":1762762520,"startTime":"0","endTime":"0","summary":"11月10日, 复宏汉霖股价涨1.39%，报收61.95元，成交金额1.1亿元，换手率1.10%，振幅5.81%，量比0.79。复宏汉霖今日主力资金净流入493.7万元，上一交易日主力净流出805.9万元。该股近5个交易日下跌10.20%，主力资金累计净流入429.4万元；近20日主力资金累计净流入3397.3万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110161619975fcd35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110161619975fcd35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161"],"gpt_icon":0},{"id":"2582828180","title":"医药生物行业：医保国谈落下帷幕；关注乳腺癌创新疗法动向","url":"https://stock-news.laohu8.com/highlight/detail?id=2582828180","media":"中泰证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582828180?lang=zh_cn&edition=full","pubTime":"2025-11-10 00:00","pubTimestamp":1762704000,"startTime":"0","endTime":"0","summary":"本周医药板块延续调整，预计主要受到医保国谈阶段压制，以及个别事件扰动。2025 年度医保国谈落下帷幕，双目录评审模式进一步支持创新链条。本次医保谈判有120 家内外资企业现场参与，其中参与基本医保药品目录谈判竞价的目录外药品127 个，参与商保创新药目录价格协商的药品24 个。此次医保谈判结果预计12 月初公布，新版药品医保目录将于2026 年1 月1 日起实施。关注乳腺癌创新疗法动向，建议关注高弹性标的Celcuity 的核心资产相关领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110155750975fc284&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110155750975fc284&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02269","LU0348783233.USD","LU0417516738.SGD","IE00BPRC5H50.USD","LU0348735423.USD","01530","LU0561508036.HKD","02268","09939","IE00B5MMRT66.SGD","LU2399975544.HKD","LU1720050803.USD","LU2476274720.SGD","02096","LU0417516571.SGD","09926","IE00B543WZ88.USD","LU0348784397.USD","BK1161","LU0348767384.USD","BK1515","02696","LU0348766576.USD","LU1794554557.SGD","LU2778985437.USD","LU0634319403.HKD","LU0540923850.HKD","BK1574","LU2488822045.USD","LU1961090484.USD","LU0417516902.SGD","LU0348827113.USD","LU0348825331.USD","LU2476274308.USD"],"gpt_icon":0},{"id":"2581314851","title":"生物医药产业将成上海第五个万亿级板块，发展成果喜人","url":"https://stock-news.laohu8.com/highlight/detail?id=2581314851","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581314851?lang=zh_cn&edition=full","pubTime":"2025-11-08 09:34","pubTimestamp":1762565657,"startTime":"0","endTime":"0","summary":"继电子信息、汽车、高端装备、软件和信息服务四大万亿级产业集群之后，上海将正式迎来第五个万亿级产业板块——生物医药。为支持生物医药产业发展，近年来上海不断出台新的政策。如今，上海生物医药产业正以蓬勃之势向万亿级目标迈进，未来有望在全球生物医药领域占据更重要地位，为我国生物医药产业发展树立榜样。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093629a49196d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108093629a49196d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06998","02696","BK1583","BK1574","06978"],"gpt_icon":0},{"id":"2581006680","title":"智通港股空仓持单统计|11月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=2581006680","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581006680?lang=zh_cn&edition=full","pubTime":"2025-11-07 18:30","pubTimestamp":1762511405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止10月31日，未平仓空单比位列前三位为中兴通讯、万科企业、中远海控，空仓比分别为17.15%、16.07%、15.03%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03800","00853","09688","01816","LU0348827113.USD","06821","03750","LU0359202008.SGD","BK1147","00763","LU0588545904.SGD","BK1190","BK1610","02899","BK1149","82318","82331","01919","BK1103","LU0196878994.USD","06682","01276","01772","02318","02331","HPAD.SI","LU0588545730.USD","01171","06865","00358","BK1619","02202","02208","02696","BK1513","PAImain","01428","06060","00772","03347","03145","LU0106252389.USD","01880","000002","BK1512","LNNGY","601318","PNGAY","LU1880383366.USD"],"gpt_icon":1},{"id":"2581046848","title":"影响重大！中国又一领域创新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046848","media":"正商参阅","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581046848?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:18","pubTimestamp":1762427880,"startTime":"0","endTime":"0","summary":"值得一提的是，正是国产创新药企的推陈出新，才有了今日中国在创新药领域的不断突破。要知道，肺癌始终高居全球及中国恶性肿瘤发病率榜首，而复宏汉霖作为深耕该领域的先行者，已成功推出9款上市产品，惠及全球超90万名患者。因为彼时，中国创新药研发尚处萌芽，进口原研生物药的高昂价格令众多患者望而却步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110619404794f33629&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110619404794f33629&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06978","02696","BK1574"],"gpt_icon":0},{"id":"2581038400","title":"复宏汉霖PD-L1 ADC肺癌新药发布关键数据，CEO朱俊：定位PD-1 联用的super ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581038400","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581038400?lang=zh_cn&edition=full","pubTime":"2025-11-06 10:36","pubTimestamp":1762396614,"startTime":"0","endTime":"0","summary":"近日，HLX43肺癌关键数据更新发布，首次合并NSCLC II期国际多中心临床研究结果，全球临床价值持续验证。他表示，复宏汉霖至少会开8个III期临床项目，预计会包括两个一线，四个二线，以及两个三线，而这8个III期临床都会集中在肺癌。业内认为，复宏汉霖估值上行的关键在于其自研PD-L1抗体偶联药物HLX43的全球潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1762338933079134283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4080","LU1169589451.USD","LU1169590202.USD","02696","ADC","BK4231","BK1161","BK4023","PD"],"gpt_icon":1},{"id":"2581779683","title":"PD-L1 ADC肺癌数据积极 复宏汉霖HLX43迎关键节点与资金考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779683","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581779683?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:31","pubTimestamp":1762353115,"startTime":"0","endTime":"0","summary":"在近日举行的“2025国际肺癌前沿及创新论坛”上，复宏汉霖更新了HLX43在非小细胞肺癌（NSCLC）研究领域的关键数据。研究数据显示，不论是在鳞状还是非鳞状NSCLC，无论EGFR突变状态、是否伴有脑转移或PD-L1表达水平如何，HLX43均观察到疗效信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511053556160251.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053556160251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4023","ADC","BK4231","PD","LU1169590202.USD","LU1169589451.USD","BK1161","02696","BK4080"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0982},{"period":"1month","weight":-0.0442},{"period":"3month","weight":-0.1974},{"period":"6month","weight":0.6944},{"period":"1year","weight":2.3136},{"period":"ytd","weight":1.8312}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0255},{"period":"3month","weight":0.0515},{"period":"6month","weight":0.1382},{"period":"1year","weight":0.3672},{"period":"ytd","weight":0.3247}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.052523},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.054687},{"month":12,"riseRate":0.833333,"avgChangeRate":0.001179}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}